HIV treatment linked to reduced risk for dry AMD : vimarsana

HIV treatment linked to reduced risk for dry AMD


HIV treatment linked to reduced risk for dry AMD
Disclosures:
Ambati reports being a co-founder of iVeena Holdings, iVeena Delivery Systems, Inflammasome Therapeutics and DiceRx; has been a consultant for Allergan, Biogen, Boehringer-Ingelheim, Immunovant, Janssen, Olix Pharmaceuticals, Retinal Solutions and Saksin LifeSciences unrelated to this work; and is named as an inventor on patent applications on AMD filed by the University of Virginia or the University of Kentucky. Please see the full study for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Related Keywords

Jayakrishna Ambati , Proceedings Of The National Academy Sciences , University Of Virginia Center , National Academy , Advanced Vision Science , Inflammasome Therapeutics , Sciences Provides Human Data Confirming Potential , Proprietary Compounds , ஜெயகிருஷ்ணா அம்பதி , பல்கலைக்கழகம் ஆஃப் வர்ஜீனியா மையம் , தேசிய கலைக்கழகம் , ப்ரொப்ரைடரீ கலவைகள் ,

© 2025 Vimarsana